Optical Head-Mounted Display Technology for Low Vision Rehabilitation
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies, Ocular |
| Therapuetic Areas: | Ophthalmology, Other |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 12/1/2018 |
| Start Date: | June 26, 2017 |
| End Date: | November 21, 2018 |
The goal of this study is to examine the ability of optical head‐mounted display technology
to enlarge the visual field of patients with severe visual field loss due to retinal
dystrophy and to improve mobility and patient‐reported outcomes.
to enlarge the visual field of patients with severe visual field loss due to retinal
dystrophy and to improve mobility and patient‐reported outcomes.
Worldwide it is estimated that 191 million people have moderate to severe visual impairment
(MSVI) and an additional 32.4 million are blind. Patients with uncorrectable MSVI may undergo
low vision rehabilitation (LVR), which has been shown to improve functional abilities, such
as mobility. However, existing LVR strategies do not adequately address severe visual field
constriction.
In this pilot study, the investigators will test the hypothesis that optical head-mounted
display (HMD) technology expands constricted visual fields and improves mobility outcomes for
patients with retinal dystrophy. We will use the Moverio HMD platform which is considered a
non-significant risk device. Outcomes for patients with retinal dystrophy will be compared to
normal age-matched controls.
(MSVI) and an additional 32.4 million are blind. Patients with uncorrectable MSVI may undergo
low vision rehabilitation (LVR), which has been shown to improve functional abilities, such
as mobility. However, existing LVR strategies do not adequately address severe visual field
constriction.
In this pilot study, the investigators will test the hypothesis that optical head-mounted
display (HMD) technology expands constricted visual fields and improves mobility outcomes for
patients with retinal dystrophy. We will use the Moverio HMD platform which is considered a
non-significant risk device. Outcomes for patients with retinal dystrophy will be compared to
normal age-matched controls.
Inclusion criteria for subjects with retinal dystrophy:
- diagnosis of retinal dystrophy
- severe vision loss that constitutes legal blindness
- able to perform a reliable Goldmann visual field test
- constricted visual field less than or equal to 20 degrees by Goldmann perimetry using
the III4e stimulus in at least one eye with best-corrected visual acuity ≥ 20/60
Inclusion criteria for control subjects:
- healthy controls
- visit history with the Comprehensive and Pediatric Ophthalmology Services at the
University of Michigan
- able to perform a reliable Goldmann visual field test
Exclusion criteria for subjects with retinal dystrophy:
- movement disorder that precludes evaluation of mobility
- functional vision loss
- pregnant women
Exclusion criteria for control subjects:
- visually significant ocular condition other than correctable refractive error
- movement disorder that precludes evaluation of mobility
- functional vision loss
- pregnant women
We found this trial at
1
site
Click here to add this to my saved trials
